Core Insights - Devonian Health Group Inc. has filed a proprietary Thykamine™ fingerprint in recent patent applications, which is a key element of its long-term intellectual property strategy [1] - The Thykamine™ fingerprint identifies eight specific chemical components in precise ratios, validated through advanced HPLC-MS methods, showing 98% confidence in batch consistency [1] - The company emphasizes the quality and consistency of Thykamine™, which has demonstrated anti-inflammatory and anti-fibrotic properties in various studies, including a Phase IIa clinical study [1] Patent Strategy - The Thykamine™ fingerprint will be systematically included in all future patent filings related to Thykamine™ [1] - This strategy aims to strengthen the company's intellectual property portfolio and regulatory preparedness for pharmaceutical development [1] Manufacturing and Quality Control - HPLC-MS methodology has shown high reproducibility across manufactured batches, confirmed by NMR analysis [1] - Potency assays using a U-937 human cell-based model validated that each batch of Thykamine™ exhibits equivalent biological activity, consistently inhibiting key inflammatory cytokines [1] Product Overview - Thykamine™, developed from Devonian's SUPREX™ platform, targets health conditions related to inflammation and oxidative stress, including ulcerative colitis and atopic dermatitis [1] - The product's anti-inflammatory, anti-oxidative, and immunomodulatory properties have been supported by numerous in vitro and in vivo studies [1] Company Background - Devonian Health Group Inc. is a clinical-stage pharmaceutical company focused on developing drugs for autoimmune fibroinflammatory diseases [1] - The company also develops high-value cosmeceutical products and operates a commercialization subsidiary, Altius Healthcare LP, for selling prescription pharmaceuticals in Canada [1]